PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2436/9/11 Shire Pharmaceuticals

AUTH/2436/9/11: Genzyme v Shire β€” VPRIV website claims (misleading comparative efficacy and manufacturing risk statements)

Shire’s VPRIV website was ruled misleading for β€œat least as effective as” (non-inferiority data), β€œdoes not require gene manipulation”, and β€œminimising the…

2018
CASE
AUTH/3119/11/18 Pfizer ⭐ Case of the Week

AUTH/3119/11/18: Director v Pfizer β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3119/11/18 (Director v Pfizer) about clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…

2018
CASE
AUTH/3099/9/18 Allergan

AUTH/3099/9/18: Director v Allergan β€” late posting of clinical trial results on EUCTR

PMCPA took up a BMJ analysis of EUCTR reporting. Allergan was found in breach of Clause 9.1 for late EUCTR results posting…

2012
CASE
AUTH/2517/6/12 ProStrakan

AUTH/2517/6/12: Anonymous v ProStrakan – Adcal-D3 Caplet promotion and sales briefing (Clause 15.9 breach)

Anonymous complaint alleged misleading trial claims and a β€œswitch programme” for Adcal-D3 Caplet. Panel found no breach for promo materials or therapy…

2012
CASE
AUTH/2495/3/12 ALK-AbellΓ³

AUTH/2495/3/12: Pharmacist v ALK-AbellΓ³ (Jext vs EpiPen) – No breach

A pharmacist alleged an ALK-AbellΓ³ rep wrongly said EpiPen was discontinued, Jext administration was identical, and Jext had 24-month shelf life. Panel…

2012
CASE
AUTH/2473/1/12 Vifor Pharma ⭐ Case of the Week

AUTH/2473/1/12: Vifor Pharma – Ferinject journal ads not UK-certified (Clause 14.1 x3)

Vifor voluntarily admitted three Ferinject ads placed by global colleagues in international journals were not certified under the UK ABPI Code. PMCPA…

2011
CASE
AUTH/2448/10/11 Boehringer Ingelheim

AUTH/2448/10/11: Pharmacist complaint about Pradaxa β€˜Stroke Prevention’ leavepieces and representative conduct (No breach on appeal)

Pharmacist challenged Pradaxa β€˜Stroke Prevention’ leavepieces and a rep’s presentation as misleading on tolerability and GI bleeding. Panel found breaches, but Appeal…

2012
CASE
Novartis Pharmaceuticals UK

Journalist v Novartis: Daily Mail article alleged to promote Xolair via third-party links (No breach)

A journalist alleged a Daily Mail Online story was covert promotion of Xolair linked to Novartis contacts and a pack shot. PMCPA…

2012
CASE
AUTH/2554/11/12 Ipsen

Ipsen: ISU Belfast meeting sponsorship criticised for overall impression of luxury venue and social programme (AUTH/2554/11/12)

Ipsen UK was ruled in breach of Clause 9.1 after supporting an ISU urology meeting at a 5-star Belfast venue where the…

2013
CASE
AUTH/2601/5/13 Gedeon Richter

Gedeon Richter breached an undertaking after a meeting invitation stayed live online without prescribing information (AUTH/2601/5/13)

An ex-employee alleged a meeting invitation remained on an events website after an undertaking was signed. The Panel ruled Gedeon Richter failed…

2013
CASE
AUTH/2575/2/13 Gedeon Richter ⭐ Case of the Week

Gedeon Richter: Barcelona Esmya meeting invitationsβ€”unacceptable arrangements, lack of certification, and pre-licence promotion (AUTH/2575/2/13)

Ex-employee complaint about Esmya meeting invites for Barcelona. Panel found unacceptable meeting arrangements and lack of certification (2013), plus promotion of an…

2013
CASE
AUTH/2626/8/13 Otsuka

Otsuka voluntary admission: RBM email set excessive call-frequency targets and was uncertified (AUTH/2626/8/13)

Otsuka admitted an RBM emailed sales teams to β€œmove” HCPs from 2–4 to 8–9 calls in a fortnight and to follow up…

2013
CASE
AUTH/2593/4/13 Shire Pharmaceuticals

AUTH/2593/4/13: Genzyme v Shire – Lancet reprint used to promote Replagal with an incorrect comparative bar chart

Shire distributed a Lancet reprint to promote Replagal that contained an incorrect bar chart comparing renal function decline vs Fabrazyme. Appeal Board…

2014
CASE
AUTH/2697/1/14 Novo Nordisk

Novo Nordisk: alleged defamatory comments about an ex-service provider employee (AUTH/2697/1/14) – No breach

An NHS commissioning lead alleged Novo Nordisk staff told nurses he’d been dismissed for misconduct. The Panel found the complainant provided no…

2015
CASE
AUTH/2816/12/15 Allergan

AUTH/2816/12/15: Anonymous v Allergan β€” allegation of large payments to doctors to endorse Botox (No breach)

Anonymous allegation that Allergan made large payments to doctors to endorse Botox and other products. Complainant provided no details and became non-contactable.…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training